(0.10%) 5 244.50 points
(0.12%) 39 584 points
(0.07%) 18 228 points
(0.72%) $79.83
(1.39%) $2.33
(0.87%) $2 360.70
(0.99%) $28.65
(0.36%) $994.40
(0.08%) $0.928
(-0.15%) $10.85
(0.06%) $0.799
(-0.77%) $91.83
-0.24% $ 5.92
Live Chart Being Loaded With Signals
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands...
Stats | |
---|---|
Volumen de hoy | 7 493.00 |
Volumen promedio | 10 261.00 |
Capitalización de mercado | 3.75B |
EPS | $0.782 ( 2023-09-30 ) |
Próxima fecha de ganancias | ( $0 ) 2024-07-25 |
Last Dividend | $0.0640 ( 2023-07-06 ) |
Next Dividend | $0 ( N/A ) |
P/E | 11.16 |
ATR14 | $0.0290 (0.49%) |
Hypera S.A. Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Hypera S.A. Finanzas
Annual | 2023 |
Ingresos: | $7.91B |
Beneficio Bruto: | $4.85B (61.30 %) |
EPS: | $2.61 |
FY | 2023 |
Ingresos: | $7.91B |
Beneficio Bruto: | $4.85B (61.30 %) |
EPS: | $2.61 |
FY | 2022 |
Ingresos: | $7.55B |
Beneficio Bruto: | $4.76B (63.10 %) |
EPS: | $2.68 |
FY | 2021 |
Ingresos: | $5.94B |
Beneficio Bruto: | $3.80B (64.05 %) |
EPS: | $2.11 |
Financial Reports:
No articles found.
Hypera S.A. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.0590 (N/A) |
$0.117 (N/A) |
$0 (N/A) |
$0.0590 (N/A) |
$0.0640 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.0770 | 2011-05-10 |
Last Dividend | $0.0640 | 2023-07-06 |
Next Dividend | $0 | N/A |
Payout Date | 2023-09-09 | |
Next Payout Date | N/A | |
# dividends | 30 | -- |
Total Paid Out | $2.45 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.13 | -- |
Div. Sustainability Score | 9.59 | |
Div.Growth Potential Score | 5.91 | |
Div. Directional Score | 7.75 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
NEFB | Ex Dividend Junior | 2023-06-29 | Semi-Annually | 0 | 0.00% | |
CNLPM | Ex Dividend Knight | 2023-07-07 | Quarterly | 0 | 0.00% | |
TINLF | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
HNFSA | Ex Dividend Junior | 2023-08-09 | Quarterly | 0 | 0.00% | |
ANPDY | Ex Dividend Knight | 2023-09-01 | Semi-Annually | 0 | 0.00% | |
PGENY | Ex Dividend Knight | 2023-06-29 | Annually | 0 | 0.00% | |
DBSDY | Ex Dividend Knight | 2023-08-11 | Quarterly | 0 | 0.00% | |
UUGRY | Ex Dividend Junior | 2023-06-22 | Semi-Annually | 0 | 0.00% | |
JMSB | Ex Dividend Junior | 2023-06-26 | Annually | 0 | 0.00% | |
BHWB | Ex Dividend Knight | 2023-07-27 | Quarterly | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.212 | 1.500 | 5.77 | 8.65 | [0 - 0.5] |
returnOnAssetsTTM | 0.0604 | 1.200 | 7.99 | 9.58 | [0 - 0.3] |
returnOnEquityTTM | 0.149 | 1.500 | 9.45 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.0801 | -1.000 | 9.20 | -9.20 | [0 - 1] |
currentRatioTTM | 1.807 | 0.800 | 5.97 | 4.77 | [1 - 3] |
quickRatioTTM | 1.314 | 0.800 | 6.98 | 5.58 | [0.8 - 2.5] |
cashRatioTTM | 0.662 | 1.500 | 7.43 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.378 | -1.500 | 3.69 | -5.54 | [0 - 0.6] |
interestCoverageTTM | 2.28 | 1.000 | -0.266 | -0.266 | [3 - 30] |
operatingCashFlowPerShareTTM | 3.08 | 2.00 | 8.97 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.866 | 2.00 | 9.07 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.910 | -1.500 | 6.36 | -9.54 | [0 - 2.5] |
grossProfitMarginTTM | 0.615 | 1.000 | 3.09 | 3.09 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.327 | 1.000 | 5.45 | 5.45 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.183 | 1.000 | -0.0935 | -0.0935 | [0.2 - 2] |
assetTurnoverTTM | 0.286 | 0.800 | -1.429 | -1.143 | [0.5 - 2] |
Total Score | 9.59 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 11.22 | 1.000 | 8.97 | 0 | [1 - 100] |
returnOnEquityTTM | 0.149 | 2.50 | 9.65 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.866 | 2.00 | 9.38 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.177 | 1.500 | 5.57 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 3.08 | 2.00 | 8.97 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.0801 | 1.500 | 9.20 | -9.20 | [0 - 1] |
pegRatioTTM | 0.0393 | 1.500 | -3.07 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.243 | 1.000 | 6.43 | 0 | [0.1 - 0.5] |
Total Score | 5.91 |
Hypera S.A.
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and similar and generic medicines under the Neo Química, Sodium Diclofenac, Hydroxyzine, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. is based in São Paulo, Brazil.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico